The University of Newcastle, Callaghan, New South Wales, Australia.
John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
Am J Speech Lang Pathol. 2021 Jan 27;30(1):301-317. doi: 10.1044/2020_AJSLP-20-00245. Epub 2021 Jan 20.
Purpose A growing number of speech-language pathologists (SLPs) are using orofacial myofunctional therapy (OMT) and/or myofunctional devices (MDs) in the treatment of their clients. However, governing bodies suggest SLPs carefully consider the availability and quality of evidence in the utilization of these therapies in speech-language pathology treatment. The purpose of this study was to review the existing evidence for OMT and MDs used by SLPs. Method A systematic quantitative review was conducted using key search terms in three electronic platforms housing multiple databases, along with a hand search, to identify additional literature. All studies published in English in full text were included if they reported pre- and posttreatment data of OMT and/or MDs provided by an SLP. Data were extracted and analyzed by the first author and confirmed by the co-authors. Results Twenty-eight studies met the criteria for inclusion in the review. Two thirds were published in the last decade and involved the use of OMT/MDs targeting multiple areas of speech pathology intervention within the same study, that is, swallowing, breathing, oral hygiene, and speech production. Majority of studies were rated as low level of evidence. All studies used OMT, with very few using MDs. While the assessment, treatment protocols, and outcome measures were highly variable, all of the studies reported an improvement in the function of the orofacial systems posttreatment. Few studies reported long-term follow-up data. Almost half of the studies recommended the use of OMT/MDs in a multidisciplinary/interdisciplinary team or in conjunction with other therapy. Conclusions There has been an increase in literature over the last decade in SLPs' use of OMT; however, there are only a small number of studies to date that explore the use of MDs. There is a growing body of evidence to support the use of OMT and MDs within a multidisciplinary team for people with communication and swallow difficulties. However, development of future research should consider investigating assessment and outcome measures, optimal dosage, and service delivery.
越来越多的言语语言病理学家（SLP）在治疗患者时使用口面肌功能治疗（OMT）和/或肌功能设备（MD）。然而，管理机构建议 SLP 在使用这些治疗方法时仔细考虑其可用性和证据质量。本研究的目的是回顾 SLP 使用的 OMT 和 MD 的现有证据。
使用三个包含多个数据库的电子平台中的关键搜索词进行系统的定量审查，并进行手工搜索以确定其他文献。如果报告了 SLP 提供的 OMT 和/或 MD 的治疗前后数据，则纳入所有以英文全文发表且报告 SLP 提供的 OMT 和/或 MD 的治疗前后数据的研究。由第一作者提取和分析数据，并由合著者确认。
28 项研究符合纳入审查的标准。其中三分之二发表于过去十年，涉及在同一研究中针对多个言语病理学干预领域使用 OMT/MD，即吞咽、呼吸、口腔卫生和言语产生。大多数研究的证据等级为低。所有研究都使用 OMT，很少使用 MD。尽管评估、治疗方案和结果测量差异很大，但所有研究均报告治疗后口面系统功能有所改善。少数研究报告了长期随访数据。几乎一半的研究建议在多学科/跨学科团队中或与其他治疗联合使用 OMT/MD。
在过去十年中，SLP 使用 OMT 的文献有所增加；然而，迄今为止，只有少数研究探讨了 MD 的使用。有越来越多的证据支持在多学科团队中使用 OMT 和 MD 来治疗有沟通和吞咽困难的患者。然而，未来的研究应考虑调查评估和结果测量、最佳剂量和服务提供。
